rapivab Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rapivab, and when can generic versions of Rapivab launch?
Rapivab is a drug marketed by Biocryst and is included in one NDA. There are two patents protecting this drug.
This drug has forty-two patent family members in fourteen countries.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.
DrugPatentWatch® Generic Entry Outlook for Rapivab
Rapivab was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 12, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for rapivab
International Patents: | 42 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 142 |
Clinical Trials: | 3 |
Patent Applications: | 1,074 |
Drug Prices: | Drug price information for rapivab |
What excipients (inactive ingredients) are in rapivab? | rapivab excipients list |
DailyMed Link: | rapivab at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for rapivab
Generic Entry Date for rapivab*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for rapivab
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Oxford | Phase 2 |
BioCryst Pharmaceuticals | Phase 3 |
Johns Hopkins University | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for rapivab
US Patents and Regulatory Information for rapivab
rapivab is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of rapivab is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting rapivab
Antiviral treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Antiviral treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
Antiviral treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Antiviral treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
Antiviral treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for rapivab
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for rapivab
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Biocryst | Alpivab | peramivir | EMEA/H/C/004299 Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. |
Withdrawn | no | no | no | 2018-04-13 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for rapivab
When does loss-of-exclusivity occur for rapivab?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06341592
Estimated Expiration: ⤷ Sign Up
Patent: 07215156
Estimated Expiration: ⤷ Sign Up
Patent: 13216632
Estimated Expiration: ⤷ Sign Up
Patent: 16262644
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0621552
Estimated Expiration: ⤷ Sign Up
Patent: 0707769
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 42260
Estimated Expiration: ⤷ Sign Up
Patent: 49090
Estimated Expiration: ⤷ Sign Up
China
Patent: 1420948
Estimated Expiration: ⤷ Sign Up
Patent: 4784166
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 5483
Estimated Expiration: ⤷ Sign Up
Patent: 0870263
Estimated Expiration: ⤷ Sign Up
Patent: 0870430
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 86626
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 12250
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 73202
Estimated Expiration: ⤷ Sign Up
Patent: 09533428
Estimated Expiration: ⤷ Sign Up
Patent: 09538822
Estimated Expiration: ⤷ Sign Up
Patent: 13256527
Estimated Expiration: ⤷ Sign Up
Patent: 15180695
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 6063
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 08010394
Estimated Expiration: ⤷ Sign Up
Patent: 08013140
Estimated Expiration: ⤷ Sign Up
Patent: 20002008
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0538
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0809012
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1992585
Estimated Expiration: ⤷ Sign Up
Patent: 2194015
Estimated Expiration: ⤷ Sign Up
Patent: 2267754
Estimated Expiration: ⤷ Sign Up
Patent: 2323339
Estimated Expiration: ⤷ Sign Up
Patent: 2475176
Estimated Expiration: ⤷ Sign Up
Patent: 080096829
Estimated Expiration: ⤷ Sign Up
Patent: 140132778
Estimated Expiration: ⤷ Sign Up
Patent: 160129105
Estimated Expiration: ⤷ Sign Up
Patent: 180024027
Estimated Expiration: ⤷ Sign Up
Patent: 190072681
Estimated Expiration: ⤷ Sign Up
Patent: 200143519
Estimated Expiration: ⤷ Sign Up
Patent: 210076189
Estimated Expiration: ⤷ Sign Up
Patent: 210135632
Estimated Expiration: ⤷ Sign Up
Patent: 230003248
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering rapivab around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20180024027 | 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) | ⤷ Sign Up |
Germany | 69840674 | ⤷ Sign Up | |
Australia | 2200199 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |